News

PARP Inhibitors: Usurping DNA Repair to Target Cancer

Publish date: June 3, 2011

 

The emerging role for PARP inhibitors in BRCA-mutated cancers is reviewed by Community Oncology Editor-in-Chief Dr. Lee Schwartzberg.

Editor-in-Chief Lee S. Schwartzberg, M.D., is the research medical director at The West Clinic in Memphis, TN.

Download the PARP Inhibitors Powerpoint Slideshow

(3.1MB)

Recommended Reading

Bone Micrometastases Show No Survival Impact in Early Breast Cancer
MDedge Hematology and Oncology
NCCN Breast Guidelines Stand by Bevacizumab
MDedge Hematology and Oncology
Sequencing Reveals MAP3K1 Mutation in Luminal-Type Breast Cancer
MDedge Hematology and Oncology
Radioactive Seeds Guide Surgeons to Nonpalpable Breast Lesions
MDedge Hematology and Oncology
Genentech Appeals to FDAs Regulatory Flexibility on Avastin
MDedge Hematology and Oncology
CDER: Avastin Breast Cancer Claim Undermines Approval Process
MDedge Hematology and Oncology
Low Vitamin D Associated With Poor Prognostic Features in Breast Cancer
MDedge Hematology and Oncology
Point/Counterpoint: Does Surgery Improve Survival in Stage IV Breast Cancer?
MDedge Hematology and Oncology
Two Studies Find Beta-Blockers Help Combat Breast Cancer Progression
MDedge Hematology and Oncology
A Phase II Tolerability Trial of Neoadjuvant Docetaxel with Carboplatin and Capecitabine in Locally Advanced Breast Cancer
MDedge Hematology and Oncology